Gelstat Corp. timeline
- 1996
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2003
- ✎Renamed Gelstat CorpFormerly Developed Technology Resource Inc.
Events of Gelstat Corp. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
Not enough history yet.
SEC filings
- Nov 21, 201210-K/AAnnual report (amended) · period to Dec 2008
- Nov 21, 201210-K/AAnnual report (amended) · period to Dec 2007
- Oct 22, 201210-KAnnual report · period to Dec 2008
- Oct 22, 201210-QQuarterly report · period to Sep 2008
- Oct 22, 201210-QQuarterly report · period to Jun 2008
- Oct 22, 201210-QQuarterly report · period to Mar 2008
- Oct 22, 201210-KAnnual report · period to Dec 2007
- Oct 22, 201210-QQuarterly report · period to Sep 2007
- Oct 22, 201210-QQuarterly report · period to Jun 2007
- Oct 22, 201210-QQuarterly report · period to Mar 2007
- Oct 19, 201210-KAnnual report · period to Dec 2006
- Oct 19, 201210-QQuarterly report · period to Sep 2006
Official filings of Gelstat Corp. with the US Securities and Exchange Commission.
Insider trading at Gelstat Corp.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Adrian Graham GoldfarbDirector | Buy | +16.00 M | — | — | 16.72 M | Form 4 |
| filed | Adrian Graham GoldfarbDirector | Buy | +8.00 M | — | — | 24.72 M | Form 4 |
| filed | Adrian Graham GoldfarbDirector | Buy | +9.84 M | — | — | 34.56 M | Form 4 |
| filed | Adrian Graham GoldfarbDirector | Buy | +53.21 M | $0.010 | $532 K | 87.77 M | Form 4 |
| filed | Adrian Graham GoldfarbDirector | Other | -280,400 | — | — | 715,400 | Form 4 |
| filed | Adrian Graham GoldfarbDirector | Other | -719,600 | — | — | 995,800 | Form 4 |
| filed | Adrian Graham GoldfarbDirector | Other | -2.05 M | — | — | 1.72 M | Form 4 |
| filed | Gerald N. Kieft IIChief Executive Officer, 10% owner | Buyindirect | +10,000 | $0.030 | $300 | 8.16 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Events at Gelstat Corp.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Acquisition or sale completed 1 · Directors and officers 9 · Material agreement 3 · Agreement ended 1 · Unregistered share sale 1
| Filed | What happened | Filing |
|---|---|---|
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersMaterial agreementAgreement endedUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Acquisition or sale completed | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of May 2, 2007
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Gelstat Corp.🇺🇸 | — | — | — | — |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Compare head to head
Similar companies by size and industry
- Eli Lilly and Company$1.20 T
- Johnson & Johnson$652.5 B
- AbbVie Inc.$514.0 B
- Roche Holding AG$370.3 B
- Merck & Co., Inc.$359.8 B
- Novartis AG$286.8 B
Sources and freshness
- Profile updated:
- Nov 4, 2026
Figures from value.today research, SEC filing.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Gelstat Corp.? Verify and update this profile — free
Show Gelstat Corp.'s ranking on your website Get the badge
The badge updates itself as the ranking changes.